PPARalpha agonist 5 is an orally available, selective partial agonist of PPARalpha (EC50: 3 nM). PPARalpha agonist 5 reduces lipid accumulation and upregulates key PPARalpha target genes, exerting anti-fatty liver effects. PPARalpha agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARgamma agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 µM). PPARalpha agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia[1].
Molekulargewicht:
368.42
Formel:
C25H20O3
Target-Kategorie:
Phosphatase,PPAR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
